Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Colorectal cancer survival disparities in the five regions of Georgia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Background/objective: The objective of this study was to examine 5-year colorectal cancer survival rates. We also determined whether demographics, tumor characteristics, and treatment modality were associated with 5-year CRC survival in the Clayton, West Central, East Central, Southeast, and Northeast Georgia regions because the significant higher CRC mortality rates in these regions in comparison to the overall rates in the State of Georgia.
      Methods: We conducted a retrospective cohort analysis using data from the 1975-2016 Surveillance, Epidemiology, and End Results program aggregated CRC patients to these five regions. Five-year CRC survival was calculated and stratified by the five regions of Georgia, using the Kaplan-Meier method with log-rank test. Cox proportional hazard regression was used to examine the mentioned association in these five regions.
      Results: Among 11,023 CRC patients, 5-year CRC survival was lowest in Clayton (65.9%) compared to the West Central (69.0%), East Central (68.2%), Southeast (70.5%), and Northeast regions (69.5%) (p-value = 0.02). In multivariable analysis, greater risk of CRC death was found in the Clayton region compared to the West Central (HR, 1.12; 95%, 1.00-1.25) region when adjusting for demographics, tumor characteristics, and treatment modality. Among Clayton Georgians, age of 75+ years (HR, 2.13; 95%, 1.56-2.89), grade 3 & 4 tumors (HR, 2.22; 95%, 1.64-3.00), and distant stage (HR, 20.95; 95%, 15.99-27.45) were negatively associated with CRC survival.
      Conclusion: We observed place-based differences in CRC survival with significantly lower survival rates in the Clayton region. Factors associated with higher risk of CRC death include older age at diagnosis, high-grade tumors, and distant stage CRC among Clayton Georgians. Our study provides important evidence to all relevant stakeholders in furthering the development of culturally tailored CRC screening interventions aimed at CRC early detection and improved outcomes.
      Competing Interests: The authors declare no potential conflict of interest.
      (Copyright: © 2024 Tsai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Eur J Cancer. 2005 Oct;41(15):2297-303. (PMID: 16140008)
      Intest Res. 2020 Jul;18(3):315-324. (PMID: 32418415)
      Soc Sci Med. 2009 Oct;69(7):1107-15. (PMID: 19695753)
      Rural Remote Health. 2019 Aug;19(3):5181. (PMID: 31394041)
      Curr Colorectal Cancer Rep. 2017;13(5):370-401. (PMID: 29104517)
      Int J Colorectal Dis. 2020 Jun;35(6):985-995. (PMID: 32314192)
      Am J Pathol. 2018 Feb;188(2):291-303. (PMID: 29128568)
      J Psychosom Res. 1992 Sep;36(6):531-41. (PMID: 1640391)
      Lancet. 2011 Jan 8;377(9760):127-38. (PMID: 21183212)
      Br J Cancer. 2005 Jun 6;92(11):1971-5. (PMID: 15900296)
      Int J Cancer. 2021 Oct 15;149(8):1553-1563. (PMID: 34164808)
      Asian Pac J Cancer Prev. 2019 Jan 25;20(1):13-21. (PMID: 30677864)
      J Rural Health. 2020 Jun;36(3):316-325. (PMID: 31454856)
      Br J Cancer. 2012 May 22;106(11):1875-80. (PMID: 22555397)
      Sci Rep. 2022 Aug 19;12(1):14143. (PMID: 35986041)
      Am J Public Health. 2000 Nov;90(11):1746-54. (PMID: 11076244)
      PLoS One. 2018 Dec 19;13(12):e0209307. (PMID: 30566456)
      Am J Prev Med. 2010 May;38(5):508-16. (PMID: 20409499)
      PLoS One. 2019 Aug 19;14(8):e0221337. (PMID: 31425558)
      BMC Cancer. 2018 Mar 1;18(1):234. (PMID: 29490625)
      Dig Dis Sci. 2015 Mar;60(3):681-91. (PMID: 25740556)
      Curr Gastroenterol Rep. 2020 Jul 9;22(8):41. (PMID: 32647903)
      Asia Pac J Oncol Nurs. 2016 Jan-Mar;3(1):98-107. (PMID: 27981145)
      Asian Pac J Cancer Prev. 2016;17(1):159-63. (PMID: 26838203)
      Prev Med. 2004 Mar;38(3):269-75. (PMID: 14766108)
      Br J Surg. 2021 Dec 1;108(12):1417-1425. (PMID: 34694371)
      World J Surg Oncol. 2014 Dec 02;12:370. (PMID: 25466394)
      Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
      NCHS Data Brief. 2008 Dec;(11):1-8. (PMID: 19389316)
      N Engl J Med. 2018 Jun 28;378(26):2456-2458. (PMID: 29949490)
      Br J Cancer. 2016 Aug 23;115(5):533-41. (PMID: 27490803)
      Lancet. 2015 Mar 14;385(9972):977-1010. (PMID: 25467588)
      Health Rep. 2016 Apr;27(4):19-27. (PMID: 27096620)
      Cancer. 2016 Jun 1;122(11):1735-48. (PMID: 26969874)
      Oncologist. 2021 Oct;26(10):e1730-e1741. (PMID: 34288237)
      Clin Colon Rectal Surg. 2009 Nov;22(4):191-7. (PMID: 21037809)
      Natl Health Stat Report. 2022 Nov;(176):1-19. (PMID: 36342825)
      JAMA Surg. 2021 Aug 1;156(8):708-709. (PMID: 34003208)
      Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1629-37. (PMID: 21750167)
    • الموضوع:
      Date Created: 20240328 Date Completed: 20240401 Latest Revision: 20240401
    • الموضوع:
      20240401
    • الرقم المعرف:
      PMC10977806
    • الرقم المعرف:
      10.1371/journal.pone.0301027
    • الرقم المعرف:
      38547204